{"id":"cd-ld-cr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD-LD CR is a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which helps to improve attention and reduce impulsivity.","oneSentence":"CD-LD CR is a controlled-release formulation of a central nervous system stimulant.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:58.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention Deficit Hyperactivity Disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00239564","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-10","conditions":"Idiopathic Parkinson's Disease","enrollment":12},{"nctId":"NCT03576638","phase":"PHASE2","title":"Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2018-07","conditions":"Parkinson Disease","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Carbidopa-levodopa controlled-release tablets"],"phase":"phase_2","status":"active","brandName":"CD-LD CR","genericName":"CD-LD CR","companyName":"Impax Laboratories, LLC","companyId":"impax-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CD-LD CR is a controlled-release formulation of a central nervous system stimulant. Used for Attention Deficit Hyperactivity Disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}